Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date
tags : Trial save search
Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
Published: 2022-07-01 (Crawled : 18:00) - prnewswire.com
ENDP | News | $0.57 22.4% -5.99% |
|
Health Technology
|
| O: -0.52%
H: 54.73%
C: 43.21%
AMRX | News | $3.36 5.66% 0.0% |
|
Health Technology
|
| O: 0.0%
H: 6.29%
C: 5.66%
opana trial
WFC CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Wells Fargo (WFC) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Class Action Filed
Published: 2022-07-01 (Crawled : 13:20) - prnewswire.com
WFC | News | $39.92 1.92% 0.2% |
|
Finance
|
| O: -0.46%
H: 3.51%
C: 3.1%
trial
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $14.09 0.36% -1.7% |
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
takhzyro children trial positive results
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-06-30 (Crawled : 17:00) - biospace.com/
FNCTF | News | $11.99 |
|
Communications
|
| O: 1.06%
H: 0.0%
C: 0.0%
BICX | $2.5 |
|
Health Care and Social Assistan...
|
| O: 6.44%
H: 0.81%
C: 0.81%
bicx104 treatment opioid for trial
Angion Ends Kidney Disease Trial while Novo Hits NASH Wall
Published: 2022-06-30 (Crawled : 14:20) - biospace.com/
ANGN | $1.11 -2.63% -1.75% |
|
|
| O: -32.75%
H: 2.61%
C: -0.87%
disease kidney trial wall nash
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
Published: 2022-06-30 (Crawled : 12:00) - globenewswire.com
BRTX | $2.9501 5.08% |
|
Professional, Scientific, and T...
|
| O: 0.58%
H: 0.58%
C: -14.98%
disease for trial
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Published: 2022-06-30 (Crawled : 12:00) - globenewswire.com
TOMDF | $0.0134 |
|
Manufacturing
|
| O: 0.0%
H: 0.75%
C: 0.75%
covid-19 trial tollovir positive biomarkers
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
Published: 2022-06-29 (Crawled : 23:00) - biospace.com/
ANGN | $1.11 -2.63% -1.75% |
|
|
| O: -1.65%
H: 0.0%
C: -4.47%
ang-3070 disease kidney trial
ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
Published: 2022-06-29 (Crawled : 22:00) - biospace.com/
CLPT | $12.5 -4.22% 0.0% |
|
Health Technology
|
| O: -1.11%
H: 3.59%
C: 2.02%
trial therapeutics therapy
89bio Seeks $94.5M for Phase III SHTG Trial
Published: 2022-06-29 (Crawled : 17:00) - biospace.com/
ETNB 3 d | $3.25 0.93% 0.93% |
|
Health Technology
|
| O: 7.27%
H: 4.88%
C: -6.5%
for trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Generac Holdings (GNRC) Investors with Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations
Published: 2022-06-29 (Crawled : 14:00) - prnewswire.com
GNRC | $217.51 3.29% -0.19% |
|
Producer Manufacturing
|
| O: 0.79%
H: 0.0%
C: -1.88%
trial
NOTV ALERT: Hagens Berman, National Trial Attorneys, Encourages Inotiv, Inc. (NOTV) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Case Filed
Published: 2022-06-29 (Crawled : 14:00) - prnewswire.com
NOTV | News J | $9.81 2.19% 0.0% |
|
Manufacturing
|
| O: -1.01%
H: 2.55%
C: -2.65%
trial
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Published: 2022-06-29 (Crawled : 13:20) - biospace.com/
ADXSD new | $3.25 |
|
n/a
|
| O: 2.15%
H: 16.57%
C: 8.13%
adxs-504 treatment for trial cancer
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseasePhase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial
Published: 2022-06-29 (Crawled : 13:20) - biospace.com/
GBT | $32.77 2.57% -1.72% |
|
Health Technology
|
| O: -0.34%
H: 10.15%
C: 8.54%
gbt601 for trial
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
Published: 2022-06-29 (Crawled : 13:00) - biospace.com/
CDAK | $2.57 -10.76% 2.43% |
|
Health Technology
|
| O: -5.04%
H: 0.0%
C: 0.0%
liver trial cancer
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
Published: 2022-06-29 (Crawled : 13:00) - biospace.com/
ACHV | $4.99 2.25% 0.21% |
|
Health Technology
|
| O: -2.9%
H: 1.99%
C: 1.0%
sciences for life trial
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
ADCT | News | $8.54 7.42% 0.0% |
|
Health Technology
|
| O: -4.93%
H: 3.94%
C: 2.23%
zynlonta trial therapeutics
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
TRVI A | $2.905 3.38% -0.36% |
|
Health Technology
|
| O: 21.67%
H: 12.55%
C: -0.81%
treatment trial therapeutics positive results haduvio
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
Published: 2022-06-29 (Crawled : 12:00) - globenewswire.com
GRTX | $1.29 -0.77% 3.85% |
|
Health Technology
|
| O: -3.9%
H: 1.35%
C: -10.81%
for trial results phase 1 rucosopasem
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
Published: 2022-06-29 (Crawled : 11:00) - globenewswire.com
ALRN | $0.2432 -6.46% 1.92% |
|
Health Technology
|
| O: -12.84%
H: 0.0%
C: -21.0%
alrn-6924 for trial therapeutics cancer
USA Holiday (Independence Day) in 2 days
Your saved searches
Save your searches and get alerts when important news are released.
Mentioned Today
APPN | News 4 | $47.15 -0.44% 4.22% |
|
Technology Services
ARQQ | News | $6.2 -1.74% -2.54% |
|
Information
CDNA | News | $22.38 4.19% 0.0% |
|
Health Technology
FNCTF | News | $11.99 |
|
Communications
HLF | News | $21.56 5.43% 0.0% |
|
Distribution Services
HYB | News | $9.16 0% |
|
Miscellaneous
NVAX | News 4 | $57.11 11.04% 0.91% |
|
Health Technology
OKTA | News 4 | $95.96 6.15% -0.61% |
|
Technology Services
OSCR | News | $4.57 7.53% 0.0% |
|
PEGA | News | $49.44 3.34% 0.0% |
|
Technology Services
PM | News 4 | $99.72 0.99% -0.07% |
|
Consumer Non-Durables
TDOC | News | $34.83 4.88% -0.4% |
|
Health Services
TILE | News | $12.695 1.24% 0.0% |
|
Producer Manufacturing
UL | News | $46.29 1.0% -0.02% |
|
Consumer Non-Durables
UNLYF | News | $45.67 |
|
Consumer Non-Durables